Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203021
Status:
COMPLETED
Last Update Posted:
2020-02-18
First Post:
2005-09-12
Brief Title:
Glatiramer Acetate Copaxone Study to Follow Participants From the First Original Study for Safety and Effectiveness
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
Open Label Study to Evaluate the Safety of Copaxone and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis RRMS Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis MS status
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 01-9004 | OTHER | Teva | None |